Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. is demonstrating strong growth potential as its EsoGuard test volume rose by 2% year-over-year to 2,841 tests in Q3 2025, reflecting both incremental quarterly increases and year-on-year gains. The company anticipates substantial revenue growth as it increases coverage from various payers, including Medicare, which will enhance its market reach and financial performance. Positive developments, such as a constructive meeting regarding Medicare coverage and increased engagement with a significant portion of the addressable population, position Lucid Diagnostics favorably for future growth and market expansion.

Bears say

Lucid Diagnostics Inc. demonstrated a negative financial performance in 3Q25, missing consensus revenue estimates while reporting a pro forma net loss of $10.3 million, which exceeded prior estimates and illustrated a concerning trajectory in earnings per share. The company's ability to gain traction with its EsoGuard product has been hindered by slower-than-anticipated adoption rates and potential issues with insurance coverage, leading to a decline in test numbers processed compared to previous quarters. Additionally, ongoing risks related to balance sheet stability, regulatory approvals, and competitive pressures further underscore the challenges facing Lucid Diagnostics, casting a shadow over its future growth prospects.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.